A Global Study to assess the Effects of Osimertinib in Participants with EGFRm Stage IA2-IA3 NSCLC following Complete Tumour Resection - ADAURA2

Exclusion Criteria

• 1. Mixed small cell and non-small cell cancer history.
• 2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection.
• 3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection.
• 4. History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
• 5. Any of the following cardiac criteria:
• - Mean resting QTcF interval > 470 ms, obtained from triplicate ECGs performed at screening.
• - Any abnormalities in rhythm, conduction, or morphology of resting ECG,
• - Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events.
• 6. History of interstitial lung disease.
• 7. Inadequate bone marrow reserve or organ function.
• 8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.
• 9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
• 10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
• 11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.